Concept

Takeda Pharmaceutical Company

Summary
The Takeda Pharmaceutical Company Limited takeꜜda jakɯçiŋ koꜜːɡjoː is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US19.299billioninrevenueduringthe2018fiscalyear.Thecompanyisfocusedononcology,rarediseases,neuroscience,gastroenterology,plasmaderivedtherapiesandvaccines.ItsheadquartersislocatedinChuoku,Osaka,andithasanofficeinNihonbashi,Chuo,Tokyo.InJanuary2012,FortuneMagazinerankedtheTakedaOncologyCompanyasoneofthe100bestcompaniestoworkforintheUnitedStates.Asof2015,ChristopheWeberwasappointedastheCEOandpresidentofTakeda.TakedaPharmaceuticalswasfoundedin1781,andwasincorporatedonJanuary29,1925.OneofthefirmsmainstaydrugsisActos(pioglitazone),acompoundinthethiazolidinedioneclassofdrugsusedinthetreatmentoftype2diabetes.Itwaslaunchedin1999.InFebruary2005,TakedaacquiredSanDiego,California,basedSyrrx,acompanyspecializinginhighthroughputXraycrystallography,forUS19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. Takeda Pharmaceuticals was founded in 1781, and was incorporated on January 29, 1925. One of the firm's mainstay drugs is Actos (pioglitazone), a compound in the thiazolidinedione class of drugs used in the treatment of type 2 diabetes. It was launched in 1999. In February 2005, Takeda acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US270 million. In February 2008, Takeda acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market. In April, Takeda acquired Millennium Pharmaceuticals of Cambridge, Massachusetts, a company specializing in cancer drug research, for US$8.8 billion. The acquisition brought in Velcade, a drug indicated for hematological malignancies, as well as a portfolio of pipeline candidates in the oncology, inflammation, and cardiovascular therapeutic areas. Millennium now operates as an independent subsidiary. In May, the company licensed non-exclusively the RNAi technology platform developed by Alnylam Pharmaceuticals, creating a potentially long-term partnership between the companies.
About this result
This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.